Tarlatamab

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
EU
  • Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
Product first approved 2026EMA
JP
  • Treatment of small cell lung cancer that has progressed after cancer chemotherapy
Product first approved 2024PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Small Cell Lung Cancer
NCT07637513 · PrECOG, LLC.
2027-01 – 2038-06 · Limited Stage Small-Cell Lung Cancer
What this study did
NCT07778316 · Amgen
2026-08-28 – 2030-07-30 · Small Cell Lung Cancer
What this study did
NCT07005128 · Amgen
2025-08-18 – 2029-08-15 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
What this study did
Other / comorbidity
NCT06937905 · Intergroupe Francophone de Cancerologie Thoracique
2026-02-06 – 2030-08-01 · Neuroendocrine Carcinoma
What this study did
Phase 2/3 (1)
Phase 2 (19)
Small Cell Lung Cancer
NCT07699237 · University of Cologne
2026-11-01 – 2031-06-30 · Extensive Disease Small Cell Lung Cancer
What this study did
NCT07242547 · Fundación GECP
2026-05-20 – 2030-06-01 · Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms
What this study did
NCT07402343 · Maastricht University Medical Center
2026-08-10 – 2030-02 · Small Cell Lung Cancer, Brain Metastases, Adult
What this study did
NCT07016230 · Gustave Roussy, Cancer Campus, Grand Paris
2025-07-02 – 2030-01-15 · Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC
What this study did
NCT07203053 · ETOP IBCSG Partners Foundation
2026-04-15 – 2029-10 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT06745323 · Amgen
2025-02-26 – 2029-08-10 · Small Cell Lung Cancer (SCLC)
What this study did
NCT07803848 · AIO-Studien-gGmbH
2025-01-01 – 2028-12-31 · Small-cell Lung Cancer
What this study did
NCT07423585 · Asrar Alahmadi
2026-03-20 – 2027-12-31 · Extensive Stage Lung Small Cell Carcinoma
What this study did
NCT06502977 · Amgen
2024-08-27 – 2027-12-10 · Extensive Stage Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07788365 · University Hospital, Strasbourg, France
2027-01-15 – 2030-08-31 · Diagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract
What this study did
NCT06893783 · Inkeun Park
2025-09-02 – 2029-04-30 · Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas, Neuroendocrine Carcinoma of Prostate
What this study did
NCT06816394 · National Taiwan University Hospital
2026-01-01 – 2029-04-30 · Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
What this study did
NCT06788938 · Jonsson Comprehensive Cancer Center
2025-03-21 – 2029-04-24 · DLL3-expressing Tumors, Advanced Tumors
What this study did
NCT06776250 · University Health Network, Toronto
2025-08-18 – 2028-03-03 · Astrocytic Tumor, Oligodendroglial Tumor
What this study did
NCT07111507 · Memorial Sloan Kettering Cancer Center
2025-07-31 – 2027-08-31 · Metastatic Prostate Cancer
What this study did
NCT07061080 · Grupo Espanol de Tumores Neuroendocrinos
2025-12-18 – 2026-09-03 · Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin
What this study did
Phase 1/2 (3)
Small Cell Lung Cancer
NCT07328490 · National Cancer Institute (NCI)
2026-04-25 – 2026-04-25 · Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
What this study did
Other / comorbidity
NCT07243470 · Centre Leon Berard
2025-11-04 – 2030-10 · Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
What this study did
NCT06814496 · University of Arizona
2025-09-08 – 2030-05 · Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
What this study did
Phase 1 (10)
Small Cell Lung Cancer
NCT07531095 · Amgen
2026-04-21 – 2031-05-21 · Small Cell Lung Cancer
What this study did
NCT07037758 · Amgen
2025-09-16 – 2031-01-18 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT05361395 · Amgen
2022-08-24 – 2030-05-30 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT06598306 · Amgen
2024-10-07 – 2030-04-24 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT03319940 · Amgen
2017-12-26 – 2027-12-31 · Small Cell Lung Carcinoma
What this study did
NCT04885998 · Amgen
2021-09-27 – 2024-09-11 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06551142 · GlaxoSmithKline
2024-09-30 – 2029-06-08 · Neoplasms
What this study did
NCT07788677 · Vall d'Hebron Institute of Oncology
2027-10-01 – 2029-05-01 · High-Grade Glioma (HGG)
What this study did
NCT04702737 · Amgen
2021-06-10 – 2024-07-22 · Neuroendocrine Prostate Cancer
What this study did
Early phase / not applicable (1)
Small Cell Lung Cancer
NCT06957314 · Memorial Sloan Kettering Cancer Center
2025-04-23 – 2028-04-23 · Small-cell Lung Cancer, Small Cell Lung Carcinoma
What this study did

Competitive landscape

This drug's own stage for Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tarlatamab: this drugApprovedMultispecific antibodyDLL3 and CD3Partial signal
NCT06211036: Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08).
NCT05740566: Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025).
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
LurbinectedinApprovedSmall moleculeAlkylating DrugPartial signalNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
ABBV-706Phase 3Antibody–drug conjugateSEZ6not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
AL8326Phase 3Small moleculeAurora B / FGFR / VEGFR (multi-kinase)Weak signal
NCT04890795: ORR 20% (6/30, 4 confirmed responses); median PFS 3.65 months; median OS 10.42 months in 30 evaluable ≥3rd-line SCLC patients (data cutoff Nov 30, 2022)
AtigotatugPhase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
GocatamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ObrixtamigPhase 3Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AlisertibPhase 2Small moleculeAurora kinase A (AURKA)not yet gradedNo reviewed efficacy summary in this indication
BMS-986525Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
DJI136Phase 1/2Cell therapyDLL3not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tarlatamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (10)
March 2027 (1)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT06830694 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-24 · NCT06598306 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-18 · NCT07016230 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-29 · NCT07803848 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Metastatic Prostate CancerRecruiting
Est. primary completion 2027-08-31 · NCT07111507 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-24 · NCT07778316 · CT.gov ↗
What to watch
December 2027 (4)
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-30 · NCT05060016 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT03319940 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT07423585 · CT.gov ↗
What to watch
Phase 2Extrapulmonary Small Cell Carcinoma and Neuroendocrine CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06816394 · CT.gov ↗
What to watch
2028 (6)
March 2028 (2)
Phase 2Astrocytic Tumor, Oligodendroglial TumorRecruiting
Est. primary completion 2028-03-03 · NCT06776250 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-18 · NCT07037758 · CT.gov ↗
What to watch
April 2028 (2)
Early phase / not applicableSmall Cell Lung CancerRecruiting
Est. primary completion 2028-04-23 · NCT06957314 · CT.gov ↗
What to watch
Phase 2DLL3-expressing Tumors, Advanced TumorsActive not recruiting
Est. primary completion 2028-04-24 · NCT06788938 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-21 · NCT07531095 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
2029 (8)
January 2029 (1)
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-01-04 · NCT07005128 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-02 · NCT07402343 · CT.gov ↗
What to watch
Phase 3Neuroendocrine CarcinomaRecruiting
Est. primary completion 2029-02-01 · NCT06937905 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas, Neuroendocrine Carcinoma of ProstateRecruiting
Est. primary completion 2029-04-30 · NCT06893783 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1High-Grade Glioma (HGG)Not yet recruiting
Est. primary completion 2029-05-01 · NCT07788677 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-10 · NCT06745323 · CT.gov ↗
What to watch
October 2029 (2)
Phase 1/2Glioma, CNS Tumor, Adult, CNS Tumor, ChildhoodRecruiting
Est. primary completion 2029-10 · NCT07243470 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-10 · NCT07203053 · CT.gov ↗
What to watch
2030 (7)
April 2030 (2)
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-04-02 · NCT06211036 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-04-20 · NCT06117774 · CT.gov ↗
What to watch
May 2030 (2)
Phase 1/2Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer …Recruiting
Est. primary completion 2030-05 · NCT06814496 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-05-30 · NCT05361395 · CT.gov ↗
What to watch
June 2030 (2)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2030-06-01 · NCT07242547 · CT.gov ↗
What to watch
Phase 2/3Small Cell Lung CancerRecruiting
Est. primary completion 2030-06-14 · NCT07226999 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Diagnosis of Neuro-endocrine Carcinoma of the Gynecological TractNot yet recruiting
Est. primary completion 2030-08-31 · NCT07788365 · CT.gov ↗
What to watch
2031 (3)
June 2031 (2)
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2031-06-23 · NCT06898957 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-06-30 · NCT07699237 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-08 · NCT07895056 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Phase 3Small Cell Lung CancerNot yet recruiting
Est. primary completion 2037-11 · NCT07637513 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultDeLLphi-305 meets its overall-survival primary endpoint at interim analysis
Amgen · Source ↗
19 November 2025ApprovalFDA grants full approval to Imdelltra in ES-SCLC
US, FDA · Source ↗